[1]
T. Wadden, “LIRAGLUTIDE 3.0 mg AS AN ADJUNCT TO INTENSIVE BEHAVIOR THERAPY IN INDIVIDUALS WITH OBESITY: SCALE IBT 56-WEEK RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL”, J ASEAN Fed Endocr Soc, vol. 34, no. 2, pp. 9–10, May 2022.